Startups
The Investor Relations website contains information about Viatris's business for stockholders, potential investors, and financial analysts.
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 14, 2022 | One company’s healthcare network is making a difference in the lives of millions | Ms Anindita Rungta never expected her daughter would need to take oral steroids but that was exactly what happened in 2012. The family had been dealing with her daughter’s eczema since she was a baby but things took a dramatic turn that yea... |
| Apr 12, 2022 | Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Nationwide Recall of One Batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), Due to the Potential for a Missing Label in the Batch | COMPANY ANNOUNCEMENT When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Read Announcement View Product... |
| Nov 8, 2021 | Q3 2021 Non-GAAP Reconciliations | Q3 2021 Non-GAAP Reconciliations November 8, 2021 Non-GAAP Financial Measures This presentation includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles general... |
| Nov 8, 2021 | Q3 2021 Earnings Presentation | Q3 2021 Earnings November 8, 2021 Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act... |
| Jul 30, 2021 | The $100 "generic" insulin | Sign up for our daily briefingMake your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes. Enter your email address Please enter a valid email. Please enter a valid email. Subscription failedSub... |
| Dec 11, 2020 | Viatris plans across-the-board cuts that could endanger 9,000 workers, 15 plants in post-merger restructuring scheme | In the high-volume generics game, size matters — and no one is quite so big as new giant on the block Viatris, which launched last month. But size can also mean redundancy, and now Viatris is plotting a major restructuring ... |